SLS
SELLAS Life Sciences Group, Inc.
$8.23
-8.96%
$1.5B
No data for this timeframe.
Vol
Market Cap$1.5B
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (83%)
Inst. Holders7 funds
Inst. Value$42.4M
Inst. Activity5 buys / 1 sells
Reddit Sentiment47° Neutral
SEC Reports3
Press Releases3
Recent Activity
Jun 2, 2026
SEC
SELLAS Life Sciences disclosed it received approximately $28.7 million in warrant exercise proceeds during April and May
8-K — Impact 3/10
May 12, 2026
SEC
SELLAS reported Q1 2026 results with a net loss of $8.4M ($-0.05 EPS) vs consensus $-0.06, a 16.7% beat. The key catalys
8-K — Impact 6/10
Apr 23, 2026
SEC
SELLAS Life Sciences Group, Inc. (SLS) has filed its definitive proxy statement for the 2026 Annual Meeting. The filing
DEFA14A — Impact 2/10
Inst.
TWO SIGMA INVESTMENTS, LP — DOUBLED
1,082,207 shares ($4.1M)
Inst.
CHARLES SCHWAB INVESTMENT MANAGEMENT — ADD
408,401 shares ($1.5M)
Jun 5, 2026
short_volume
Short Volume: SLS — 55.3% short (2.0M / 3.6M)
Short: 2,015,132 | Exempt: 72,711 | TRF Vol: 3,645,296 | Short Ratio: 55.3% | Off-exchange volume (d
Mar 19, 2026
Press
SELLAS Life Sciences reported financial results for 2025, showing reduced net loss and a strong cash position bolstered
Impact 6/10
Mar 17, 2026
Press
SELLAS Life Sciences announced preclinical data for its CDK9 inhibitor SLS009 (tambiciclib) showing potent apoptosis ind
Impact 5/10
Price Targets
$10.00
+21.5% upside
Strong Buy
Current $8.23
Low $10.00
Median $10.00
High $10.00
2 analysts
$10.00
$10.00
Analyst Ratings
1Strong Buy
4Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Mar 12, 2026 | Maxim Group | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.05 ▲ +25.0% | $-0.05 — $-0.05 | 29% YoY | 2 |
| Next Q | $-0.06 ▲ +25.0% | $-0.06 — $-0.05 | 8% YoY | 2 |
| Current FY | $-0.21 ▲ +25.9% | $-0.22 — $-0.20 | 16% YoY | 2 |
| Next FY | $-0.15 ▲ +16.7% | $-0.25 — $-0.05 | 29% YoY | 2 |
Latest Reports
NEUTRAL
8-K
3/10
SELLAS Life Sciences disclosed it received approximately $28.7 million in warrant exercise proceeds during April and May
Jun 2, 2026
NEUTRAL
8-K
6/10
SELLAS reported Q1 2026 results with a net loss of $8.4M ($-0.05 EPS) vs consensus $-0.06, a 16.7% beat. The key catalys
May 12, 2026
MIXED
Press
6/10
SELLAS Life Sciences reported financial results for 2025, showing reduced net loss and a strong cash position bolstered
Mar 19, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $31.9M | DOUBLED |
| TWO SIGMA INVESTMENTS, LP | $4.1M | DOUBLED |
| MORGAN STANLEY | $3.4M | DOUBLED |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $1.5M | ADD |
| WELLS FARGO & COMPANY/MN | $1.1M | DOUBLED |
Reddit Sentiment
47°▼
Neutral
Bearish
Neutral
Bullish
7 institutional holders with $42.4M total value (11,256,672 shares) as of 2025-Q4. Top holders: VANGUARD, TWO, MORGAN. Net buying activity: 5 institutions added/increased vs 1 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 8,467,400 | $31.9M | 75.2% | DOUBLED +134.4% |
| 2 | TWO SIGMA INVESTMENTS, LP | 1,082,207 | $4.1M | 9.6% | DOUBLED +642.0% |
| 3 | MORGAN STANLEY | 890,929 | $3.4M | 7.9% | DOUBLED +1532.0% |
| 4 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 408,401 | $1.5M | 3.6% | ADD +38.9% |
| 5 | WELLS FARGO & COMPANY/MN | 299,305 | $1.1M | 2.7% | DOUBLED +294.5% |
| 6 | BANK OF AMERICA CORP /DE/ | 100,935 | $380.5K | 0.9% | DOUBLED +139.5% |
| 7 | FMR LLC | 7,495 | $28.3K | 0.1% | DOUBLED +629.1% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 145,856 | 1,082,207 | +642.0% | $4.1M | 2025-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 294,106 | 408,401 | +38.9% | $1.5M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | DOUBLED | 75,867 | 299,305 | +294.5% | $1.1M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 42,150 | 100,935 | +139.5% | $380.5K | 2025-Q4 |
| FMR LLC | DOUBLED | 1,028 | 7,495 | +629.1% | $28.3K | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 291,822 | 0 | -100.0% | $0.00 | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 291,822 | — | $469.8K | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 197,642 | 145,856 | -26.2% | $234.8K | 2025-Q3 |
| UBS Group AG | TRIM | 309,687 | 84,989 | -72.6% | $136.8K | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | ADD | 53,815 | 75,867 | +41.0% | $122.1K | 2025-Q3 |
| VANGUARD GROUP INC | DOUBLED | 2,839,318 | 6,654,799 | +134.4% | $14.6M | 2025-Q2 |
| MORGAN STANLEY | DOUBLED | 66,450 | 1,084,478 | +1532.0% | $2.4M | 2025-Q2 |
| UBS Group AG | DOUBLED | 62,231 | 309,687 | +397.6% | $678.2K | 2025-Q2 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | DOUBLED | 16,238 | 294,106 | +1711.2% | $644.1K | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 48,287 | 197,642 | +309.3% | $432.8K | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | DOUBLED | 3,003 | 53,815 | +1692.0% | $117.9K | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 622 | 34,579 | +5459.3% | $75.7K | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 34,892 | 0 | -100.0% | $0.00 | 2025-Q2 |
| MORGAN STANLEY | DOUBLED | 15,778 | 66,450 | +321.2% | $71.8K | 2025-Q1 |
| UBS Group AG | TRIM | 127,821 | 62,231 | -51.3% | $67.2K | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 48,287 | — | $52.1K | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 34,892 | — | $37.7K | 2025-Q1 |
| CITADEL ADVISORS LLC | DOUBLED | 284,819 | 740,417 | +160.0% | $770.0K | 2024-Q4 |
| UBS Group AG | NEW | — | 127,821 | — | $132.9K | 2024-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 92,937 | 0 | -100.0% | $0.00 | 2024-Q4 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
3 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 3 neutral. Avg impact: 3.7/10.
NEUTRAL
8-K
3/10
SELLAS Life Sciences disclosed it received approximately $28.7 million in warrant exercise proceeds
Jun 2, 2026
NEUTRAL
8-K
6/10
SELLAS reported Q1 2026 results with a net loss of $8.4M ($-0.05 EPS) vs consensus $-0.06, a 16.7% b
May 12, 2026
NEUTRAL
DEFA14A
2/10
SELLAS Life Sciences Group, Inc. (SLS) has filed its definitive proxy statement for the 2026 Annual
Apr 23, 2026
MIXED
6/10
SELLAS Life Sciences reported financial results for 2025, showing reduced net loss and a strong cash
Mar 19, 2026
MIXED
5/10
SELLAS Life Sciences announced preclinical data for its CDK9 inhibitor SLS009 (tambiciclib) showing
Mar 17, 2026
BULLISH
7/10
SELLAS Life Sciences has enrolled the first patient in a Phase 2 trial for its CDK9 inhibitor SLS009
Mar 12, 2026
Current analyst consensus: Strong Buy (83% buy). Based on 6 analysts: 1 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$10.00 mean target
+21.5% upside
Strong Buy (3.00)
$10.00 Low
$10.00 High
| Metric | Value |
|---|---|
| Current Price | $8.23 |
| Target Low | $10.00 |
| Target Mean | $10.00 |
| Target Median | $10.00 |
| Target High | $10.00 |
| # Analysts | 2 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.05 | $-0.05 | $-0.05 | 28.6% | +25.0% | — | $0.0B | 0.0% | 2 |
| Next Q 2026-09-30 |
$-0.06 | $-0.06 | $-0.05 | 8.3% | +25.0% | 1↑ 1↓ | $0.0B | 0.0% | 2 |
| Current FY 2026-12-31 |
$-0.21 | $-0.22 | $-0.20 | 16.0% | +25.9% | 2↑ 0↓ | $0.0B | 0.0% | 2 |
| Next FY 2027-12-31 |
$-0.15 | $-0.25 | $-0.05 | 28.6% | +16.7% | 2↑ 1↓ | $0.0B | 0.0% | 2 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.050 | |
| 7d ago | $-0.070 | +0.020 |
| 30d ago | $-0.067 | +0.017 |
| 60d ago | $-0.067 | +0.017 |
| 90d ago | $-0.067 | +0.017 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Mar 12, 2026 | Maxim Group | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 1 | 4 | 1 | 0 | 0 | 83% | |
| May 1, 2026 | 1 | 4 | 1 | 0 | 0 | 83% | |
| Apr 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Mar 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Feb 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Jan 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
47°
Neutral
Bearish
Neutral
Bullish
31 mentions
9 bullish
11 bearish
30 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Jun 6, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Jun 6, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Jun 2, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Jun 2, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Jun 1, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Jun 1, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Jun 1, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 26, 2026 | 2 | 50° Neutral | 0 | 0 | 2 |
| May 26, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| May 21, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| May 21, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| May 20, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| May 20, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| May 17, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 17, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 16, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| May 16, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| May 16, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| May 13, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 13, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 26, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 26, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 24, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Apr 24, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Apr 20, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Apr 20, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Apr 9, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Apr 9, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Apr 8, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Apr 8, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
Recent Reddit Threads
$SLS Part 2 and FINAL (Deepest Due Diligence for REGAL Trial) (From a Deep Value Investor) (Predicting BAT mOS from Predictive Model)
▲ 153
💬 106
⚡ 4.2
Do you guys think $SLS really is a big opportunity?
▲ 42
💬 37
⚡ 0.7
Three names I’ve been looking at lately — AI energy, oncology trials & US rare earth supply (SES, SLS, USAR)
▲ 1
💬 1
⚡ 0.5
Full porting $SLS
▲ 1
💬 0
⚡ 0.5
NUAI, CING, SLS or FEMY…
▲ 1
💬 1
⚡ 0.5
SLS, NBIS or SNXX for this coming week
▲ 1
💬 0
⚡ 0.5
SLS $10k call degeneracy and update
▲ 1
💬 1
⚡ 0.5
Tell me how you really feel
▲ 1
💬 1
⚡ 0.5
Options changed my life pt.4
▲ 1
💬 1
⚡ 0.5
SLS still shadow banned around here?
▲ 1
💬 1
⚡ 0.5
How do you feel about SLS and IBRX?
▲ 1
💬 1
⚡ 0.5
$SLS Lunch money profits
▲ 1
💬 1
⚡ 0.5
SLS, NBIS or SNXX for this coming week
▲ 1
💬 0
⚡ 0.5
$SLS (Deepest Due Diligence for SLS-009, Machine Learning Models and Results, and Buyout Deep DD) (From a Deep Value Investor)
▲ 1
💬 1
⚡ 0.5
Portfolio in the middle of doom and gloom for SaaS.
▲ 1
💬 1
⚡ 0.5
Jun 5, 2026
short_volume
Short Volume: SLS — 55.3% short (2.0M / 3.6M)
Short: 2,015,132 | Exempt: 72,711 | TRF Vol: 3,645,296 | Short Ratio: 55.3% | Off-exchange volume (dark pool + OTC)
Jun 3, 2026
short_volume
Short Volume: SLS — 63.2% short (2.5M / 3.9M)
Short: 2,490,896 | Exempt: 6,781 | TRF Vol: 3,941,000 | Short Ratio: 63.2% | Off-exchange volume (dark pool + OTC)
Jun 2, 2026
short_volume
Short Volume: SLS — 64.5% short (3.5M / 5.5M)
Short: 3,536,554 | Exempt: 11,361 | TRF Vol: 5,486,002 | Short Ratio: 64.5% | Off-exchange volume (dark pool + OTC)
Jun 1, 2026
short_volume
Short Volume: SLS — 59.4% short (2.2M / 3.7M)
Short: 2,221,975 | Exempt: 43,052 | TRF Vol: 3,738,809 | Short Ratio: 59.4% | Off-exchange volume (dark pool + OTC)
May 28, 2026
short_volume
Short Volume: SLS — 58.7% short (3.5M / 6.0M)
Short: 3,545,788 | Exempt: 79,561 | TRF Vol: 6,040,567 | Short Ratio: 58.7% | Off-exchange volume (dark pool + OTC)
May 22, 2026
short_volume
Short Volume: SLS — 60.9% short (3.4M / 5.6M)
Short: 3,421,121 | Exempt: 435,905 | TRF Vol: 5,618,914 | Short Ratio: 60.9% | Off-exchange volume (dark pool + OTC)
May 21, 2026
short_volume
Short Volume: SLS — 61.8% short (8.4M / 13.6M)
Short: 8,425,002 | Exempt: 555,823 | TRF Vol: 13,622,871 | Short Ratio: 61.8% | Off-exchange volume (dark pool + OTC)
May 20, 2026
short_volume
Short Volume: SLS — 64.1% short (6.4M / 10.0M)
Short: 6,436,777 | Exempt: 54,857 | TRF Vol: 10,046,549 | Short Ratio: 64.1% | Off-exchange volume (dark pool + OTC)
May 19, 2026
short_volume
Short Volume: SLS — 55.0% short (2.2M / 4.0M)
Short: 2,206,446 | Exempt: 19,932 | TRF Vol: 4,008,262 | Short Ratio: 55.0% | Off-exchange volume (dark pool + OTC)
May 18, 2026
short_volume
Short Volume: SLS — 59.2% short (2.7M / 4.6M)
Short: 2,723,211 | Exempt: 36,984 | TRF Vol: 4,600,489 | Short Ratio: 59.2% | Off-exchange volume (dark pool + OTC)
May 15, 2026
short_volume
Short Volume: SLS — 60.5% short (2.6M / 4.2M)
Short: 2,570,714 | Exempt: 24,508 | TRF Vol: 4,247,506 | Short Ratio: 60.5% | Off-exchange volume (dark pool + OTC)
May 14, 2026
short_volume
Short Volume: SLS — 55.1% short (5.1M / 9.3M)
Short: 5,099,030 | Exempt: 79,610 | TRF Vol: 9,252,003 | Short Ratio: 55.1% | Off-exchange volume (dark pool + OTC)
May 14, 2026
short_interest
FTD: SLS — 84,995 shares ($0.6M) failed to deliver
Settlement: 20260514, Price: $6.53, FTD Value: $555,017.35, SELLAS LIFE SCIENCES GROUP INC
May 12, 2026
short_volume
Short Volume: SLS — 61.9% short (0.9M / 1.5M)
Short: 940,606 | Exempt: 19,675 | TRF Vol: 1,520,464 | Short Ratio: 61.9% | Off-exchange volume (dark pool + OTC)
May 11, 2026
earnings_calendar
SLS Q1 2026 Earnings Scheduled — 2026-05-11